Glanz: Aging daily b1de0c2b9a8f49a2a3542c500ab4bae3 951b32e30ebf

2026-09-28T21:30:04Z

Aging daily b1de0c2b9a8f49a2a3542c500ab4bae3 951b32e30ebf

Neue Seite

__NOTOC__
<div class="aging-research-world aging-journal" lang="en">
<div class="aj-masthead"><div class="aj-brand"><span class="aj-monogram">[[Aging|a.]]</span><span>[[Aging|AGING]]<small>RESEARCH IN PROGRESS</small></span></div><div class="aging-languages" role="navigation" aria-label="Sprache / Language"><span class="aging-language" title="Deutsch">[[Altern/Erkenntniskette|🇩🇪]]</span><span class="aging-language" title="English">[[Aging/Evidence chain|🇬🇧]]</span></div></div>
<div class="aj-context"><strong>An evolving AI research project</strong>[[Aging/About the project|Background · goals · methods]]<span>Updated 28 Sep 2026</span></div>
<h1>Evidence chain</h1>
<div class="aj-article">

'''Reasoning chain and claim ledger''' · 28 September 2026

This ledger preserves reasoning across sessions. It separates external findings, project inferences and missing evidence. More text or more AI voices do not increase evidence.

== The path so far ==
Axolotl regeneration and neuronal protein control → separate questions of initiation and maintenance → focused AG-T01 model → function, synapse preservation and degradation as joint decisions → human trials as benchmarks for specific, bounded outcome claims.

Arrows describe the development of our reasoning, not an established biological causal chain.

== AG-C01 · Functional benefit requires a specific endpoint, not a label of general rejuvenation. ==
'''Project level 1'''

* '''What changed:''' The mobility perspective extends the previously molecular emphasis.
* '''Project inference:''' Every candidate receives a defined functional endpoint and target population.
* '''Testable prediction:''' A separate, comparable study should show a meaningful functional advantage for this mobility approach over its prespecified control; precision and transferability govern appraisal.
* '''Next countercheck:''' Check long-term outcomes, harms and separate comparison cohorts.
* Source anchors: [https://jamanetwork.com/journals/jama/fullarticle/1875328 AG-J01]

== AG-C02 · Related programs in separate cohorts permit limited transfer checks, not isolation of individual active components. ==
'''Project level 1'''

* '''What changed:''' Human evidence gains a second endpoint type: cognitive test performance.
* '''Project inference:''' Test performance, everyday function and dementia incidence are maintained as distinct claims.
* '''Testable prediction:''' A small incremental test advantage should be testable under similar conditions and comparable analysis; a precise null or absent daily relevance narrows the corresponding claim.
* '''Next countercheck:''' Compare counterstudies, active comparators, practice effects and longer-term clinical endpoints.
* Source anchors: [https://www.sciencedirect.com/science/article/pii/S0140673615604615 AG-J02]; [https://jamanetwork.com/journals/jama/fullarticle/2837046 AG-J03]

== AG-C03 · Selective cargo degradation could support neuronal function if useful synapses survive. ==
'''Project level 2'''

* '''What changed:''' The target now has conjunctive measurements and an explicit partial-mediation test.
* '''Project inference:''' The combined chain is project synthesis; no cited individual finding establishes it completely.
* '''Testable prediction:''' Under controlled loading, verified degradation should coincide with preserved synapses and meaningful functional improvement; selective process restriction should attenuate a prespecified meaningful portion of benefit.
* '''Next countercheck:''' Check prior evidence independently and validate whether the balance can be measured before further prioritisation.
* Source anchors: [https://www.nature.com/articles/s41467-026-74906-z AG-R01]; [https://www.nature.com/articles/s41586-025-09987-9 AG-R02]; [https://www.eneuro.org/content/10/6/ENEURO.0031-23.2023 AG-R08]

== AG-C04 · A favourable marker does not automatically establish function or reversal. ==
'''Project level 1'''

* '''What changed:''' Candidate entries now display restrictions and counterevidence alongside opportunities.
* '''Project inference:''' Record markers, function and baseline impairment separately.
* '''Testable prediction:''' Improved markers alongside a sufficiently precise absence of functional benefit would constrain the tested functional claim; imprecise data leave it unresolved.
* '''Next countercheck:''' Check comparable ages, genetic backgrounds, endpoints and controls.
* Source anchors: [https://www.nature.com/articles/s41514-026-00351-3 AG-R03]

== AG-C05 · The FTL1–redox–DUB chain remains unconfirmed. ==
'''Project level 2'''

* '''What changed:''' Retained as a side branch; repetition does not upgrade it.
* '''Project inference:''' Thematically compatible findings do not create a causal link.
* '''Testable prediction:''' FTL1 manipulation should precede a selective DUB change; an appropriate counter-perturbation should alter the relevant functional contribution.
* '''Next countercheck:''' Seek direct joint tests and competing metabolic pathways.
* Source anchors: [https://www.nature.com/articles/s41467-026-71921-y AG-S08]; [https://www.nature.com/articles/s43587-025-00940-z AG-S09]

== AG-C06 · Initiating regeneration and maintaining lasting function remain separate tests. ==
'''Project level 2'''

* '''What changed:''' AG-H01 serves as a framework, not a confirmed new result.
* '''Project inference:''' Axolotl findings generate comparative questions; a human aging benefit needs its own evidence chain.
* '''Testable prediction:''' Successful transfer should demonstrate correct functional integration and durability in the target model alongside tissue regrowth.
* '''Next countercheck:''' Compare species, cell types and injury context; establish team and dataset overlap.
* Source anchors: [https://pubmed.ncbi.nlm.nih.gov/37879337/ AG-S01]; [https://www.nature.com/articles/s41586-025-09036-5 AG-S03]

== Which evidence routes are independent? ==
* FINGER and US POINTER: separate cohorts; related programs, different comparators and partially shared investigators. Dataset independence is not complete methodological independence.
* LIFE and US POINTER: different cohorts and endpoints, with some shared investigators. They do not replicate the same effect.
* AG-T01: origin tracing, microglial intervention and alternative mechanisms provide distinct perspectives. They do not yet establish the combined mediation chain. Multiple assays within one study are not independent laboratory replication.
* Axolotl sources: different questions; full team/data independence has not been audited.
* Secondary reports, reviews and meta-analyses of the same datasets are not counted as new replications. Internal AI checks are not experimental evidence routes.

== Numbers without false precision ==
The values below are published estimates from the study teams, not project calculations. Different outcomes and comparators are not pooled into an overall score.
{| class="wikitable"
! Source !! Published estimate !! Limit
|-
| [https://jamanetwork.com/journals/jama/fullarticle/1875328 AG-J01 · LIFE] || HR 0.82; 95% CI 0.69–0.98 || Mobility endpoint, not “biological age”.
|-
| [https://www.sciencedirect.com/science/article/pii/S0140673615604615 AG-J02 · FINGER] || ΔNTB-Z/year 0.022; 95% CI 0.002–0.042 || Composite test score.
|-
| [https://jamanetwork.com/journals/jama/fullarticle/2837046 AG-J03 · US POINTER] || ΔSD/year 0.029; 95% CI 0.008–0.050 || Structured versus self-guided.
|}

'''Next update:''' inspect unresolved questions and data dependence first, then update only claims whose assessment actually changed. Missing independent evidence remains a gap; precise counterevidence can end a direction. [[Aging/About the project|Project, goals and methods]] · [[Aging/Approaches to aging|Growing list of approaches]]

</div>
<div class="aj-section-title"><h2>Continue exploring</h2></div><div class="aj-tiles"><div class="aj-tile"><div class="aj-thumb">[[File:Bovine Pulmonary Artery Endothelial Cells Fluorescent Image.jpg|120px|frameless|link=Aging/Approaches to aging|alt=Fluorescence micrograph of bovine endothelial cells with labeled nuclei, actin and mitochondria.]]</div><div><div class="aj-tile-title">[[Aging/Approaches to aging|Approaches to aging]]</div><div class="aj-tile-desc">Evidence and functional outcomes</div></div></div><div class="aj-tile"><div class="aj-thumb">[[File:DNA double helix.svg|120px|frameless|link=Aging/Research colloquium|alt=Schematic illustration of a DNA double helix.]]</div><div><div class="aj-tile-title">[[Aging/Research colloquium|Research colloquium]]</div><div class="aj-tile-desc">16 foundation assignments + 4 new deep dives</div></div></div></div>
<div class="aj-footer"><div class="aj-brand"><span class="aj-monogram">[[Aging|a.]]</span><span>[[Aging|AGING]]<small>RESEARCH IN PROGRESS</small></span></div><div class="aj-context">[[Aging|Project overview]][[Aging/About the project|Goals & methods]][[Aging/Evidence chain|Evidence chain]]</div><div class="aj-meta">AI-assisted literature research and model building. No laboratory or clinical studies conducted by this project. No personal treatment plans.</div><div class="aj-credits">Image credits · Illustrations, not project data: [https://commons.wikimedia.org/wiki/File:Axolotl_Portrait.jpg Axolotl] — LoKiLeCh ([https://creativecommons.org/licenses/by-sa/3.0/ CC BY-SA 3.0]) · [https://commons.wikimedia.org/wiki/File:XBio_illustration_%E2%80%93_Neuron.png Neuron] — explorebiology (Explore Biology) ([https://creativecommons.org/licenses/by/4.0/ CC BY 4.0]) · [https://commons.wikimedia.org/wiki/File:DNA_double_helix.svg DNA] — Biochemlife ([https://creativecommons.org/licenses/by-sa/4.0/ CC BY-SA 4.0]) · [https://commons.wikimedia.org/wiki/File:Bovine_Pulmonary_Artery_Endothelial_Cells_Fluorescent_Image.jpg Bovine endothelial cells] — Erin Rod ([https://creativecommons.org/licenses/by/4.0/ CC BY 4.0])</div></div>
</div>
[[Category:Altern / Aging]]

Aging/Evidence chain - Versionsgeschichte

Glanz: Aging daily b1de0c2b9a8f49a2a3542c500ab4bae3 951b32e30ebf